JP2005503374A - 女性の性的欲求および性的反応性を高めるためのアンドロゲン作用薬の随時投与 - Google Patents

女性の性的欲求および性的反応性を高めるためのアンドロゲン作用薬の随時投与 Download PDF

Info

Publication number
JP2005503374A
JP2005503374A JP2003516531A JP2003516531A JP2005503374A JP 2005503374 A JP2005503374 A JP 2005503374A JP 2003516531 A JP2003516531 A JP 2003516531A JP 2003516531 A JP2003516531 A JP 2003516531A JP 2005503374 A JP2005503374 A JP 2005503374A
Authority
JP
Japan
Prior art keywords
agonist
testosterone
pge
androgenic
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003516531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503374A5 (https=
Inventor
レランド エフ． ウィルソン，
ピーター ワイ． タム，
Original Assignee
ヴィヴァス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィヴァス・インコーポレイテッド filed Critical ヴィヴァス・インコーポレイテッド
Publication of JP2005503374A publication Critical patent/JP2005503374A/ja
Publication of JP2005503374A5 publication Critical patent/JP2005503374A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003516531A 2001-07-27 2002-07-26 女性の性的欲求および性的反応性を高めるためのアンドロゲン作用薬の随時投与 Withdrawn JP2005503374A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/919,472 US20020013304A1 (en) 1997-10-28 2001-07-27 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
PCT/US2002/023847 WO2003011301A1 (en) 2001-07-27 2002-07-26 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness

Publications (2)

Publication Number Publication Date
JP2005503374A true JP2005503374A (ja) 2005-02-03
JP2005503374A5 JP2005503374A5 (https=) 2005-12-22

Family

ID=25442156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003516531A Withdrawn JP2005503374A (ja) 2001-07-27 2002-07-26 女性の性的欲求および性的反応性を高めるためのアンドロゲン作用薬の随時投与

Country Status (5)

Country Link
US (1) US20020013304A1 (https=)
EP (1) EP1420795A4 (https=)
JP (1) JP2005503374A (https=)
CA (1) CA2455728A1 (https=)
WO (1) WO2003011301A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523856A (ja) * 2003-06-18 2007-08-23 トラスティーズ・オブ・ダートマウス・カレッジ 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法
JP2014001235A (ja) * 2006-11-03 2014-01-09 Emotional Medical Bv 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
US9192669B2 (en) 2004-05-11 2015-11-24 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9333203B2 (en) 2005-11-11 2016-05-10 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1235563A2 (en) * 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020132832A1 (en) * 2001-01-05 2002-09-19 Mills Thomas M. Treatment of erectile dysfunction
DE60216630T2 (de) * 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
CA2484318C (en) * 2002-05-01 2014-01-28 Mcneil-Ppc, Inc. Warming and nonirritating lubricant antifungal gel compositions
US7005408B2 (en) * 2002-05-01 2006-02-28 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US7658941B2 (en) * 2002-05-01 2010-02-09 Johnson & Johnson Consumer Companies, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US7695730B2 (en) * 2002-05-01 2010-04-13 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
WO2004005324A2 (en) * 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
AU2003274823A1 (en) * 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
CA2533013C (en) * 2003-07-17 2011-07-26 Banner Pharmacaps, Inc. Controlled release preparations
US20090053163A1 (en) * 2003-10-30 2009-02-26 Nawaz Ahmad Warming and nonirritating lubricant compositions and method of comparing irritation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2005058342A1 (en) * 2003-12-16 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating ovulation
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
EA200700388A1 (ru) 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) * 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
NZ556202A (en) * 2005-01-04 2010-03-26 Teikoku Pharma Usa Inc Cooling topical patch preparation
DE602006006432D1 (de) 2005-03-24 2009-06-04 Nolabs Ab Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
EP1868590A4 (en) * 2005-04-13 2012-08-29 Unimed Pharmaceuticals Inc PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US7851419B2 (en) * 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
ES3012497T3 (en) 2005-10-12 2025-04-09 Besins Healthcare Lu Sarl Improved testosterone gel and method of use
CA2614345C (en) * 2005-10-24 2013-01-08 Teikoku Pharma Usa, Inc. Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
WO2008068584A2 (en) * 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
BRPI0819707A2 (pt) * 2007-11-29 2015-06-16 Allergan Inc Ciclopentanos substituídas tendo atividade de prostaglandina
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011022652A1 (en) * 2009-08-21 2011-02-24 Novan, Inc. Topical gels
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
ES2804263T3 (es) 2011-07-05 2021-02-05 Novan Inc Composiciones tópicas
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
US20140045804A1 (en) * 2012-01-19 2014-02-13 Edward M. Lichten Treatment of hypoactive sexual disorder (hsdd)
AU2013232576B2 (en) 2012-03-14 2016-09-01 Ligand Pharmaceuticals Incorporated Nitric oxide releasing pharmaceutical compositions
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
EP2689781A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol composition
EP2754442A1 (en) 2013-01-09 2014-07-16 Ferring B.V. Misoprostol for the induction of labour
WO2014016394A1 (en) 2012-07-26 2014-01-30 Ferring B.V. Misprostol composition
EP2754443A1 (en) 2013-01-09 2014-07-16 Ferring B.V. Misoprostol for the induction of labour
EP2877182A1 (en) 2012-07-26 2015-06-03 Ferring B.V. Misoprostol formulation
EP2689802A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol formulation
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
KR102321169B1 (ko) 2013-08-08 2021-11-02 노반, 인크. 국소 조성물 및 그의 사용 방법
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN106659675B (zh) 2014-07-11 2023-07-04 诺万公司 局部抗病毒组合物和其使用方法
CA2919733A1 (en) 2014-08-08 2016-02-08 Novan, Inc. Topical compositions and methods of using the same
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
EP3423100A4 (en) 2016-03-02 2019-10-16 Novan, Inc. COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF
CN109310630A (zh) 2016-04-13 2019-02-05 诺万公司 用于治疗感染的组合物、系统、试剂盒和方法
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070757A (ko) * 1997-02-07 2000-11-25 에버트 챨스 디 테스토스테론 결핍증이 나타나는 여성에게 테스토스테론을 보충하는 방법 및 이에 이용되는 조성물
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523856A (ja) * 2003-06-18 2007-08-23 トラスティーズ・オブ・ダートマウス・カレッジ 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法
US9192669B2 (en) 2004-05-11 2015-11-24 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9700566B2 (en) 2004-05-11 2017-07-11 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US10441592B2 (en) 2004-05-11 2019-10-15 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9333203B2 (en) 2005-11-11 2016-05-10 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9737548B2 (en) 2005-11-11 2017-08-22 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2014001235A (ja) * 2006-11-03 2014-01-09 Emotional Medical Bv 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
JP2015157849A (ja) * 2006-11-03 2015-09-03 イービー アイピー ライブリドス ビー．ブイ． 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
US9211334B2 (en) 2006-11-03 2015-12-15 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
US9597335B2 (en) 2006-11-03 2017-03-21 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
JP2017132809A (ja) * 2006-11-03 2017-08-03 イービー アイピー ライブリドス ビー．ブイ． 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
US10314848B2 (en) 2006-11-03 2019-06-11 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction

Also Published As

Publication number Publication date
US20020013304A1 (en) 2002-01-31
CA2455728A1 (en) 2003-02-13
EP1420795A4 (en) 2006-09-06
WO2003011301A1 (en) 2003-02-13
EP1420795A1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
JP2005503374A (ja) 女性の性的欲求および性的反応性を高めるためのアンドロゲン作用薬の随時投与
US7226910B2 (en) Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
JP2005500347A (ja) 女性の性的欲求および反応性を高めるための経口活性アンドロゲン作用薬の随時投与
US20050070516A1 (en) As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6469016B1 (en) Treatment of female sexual dysfunction using phosphodiesterase inhibitors
US5877216A (en) Treatment of female sexual dysfunction
US20040044080A1 (en) Treatment of dyspareunia with topically administered nitroglycerin formulations
US6284263B1 (en) Buccal drug administration in the treatment of female sexual dysfunction
JP5441966B2 (ja) 活性薬の経皮又は経粘膜適用のための使用及び製剤
US20040014761A1 (en) Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20070154533A1 (en) Method of increasing testosterone and related steriod concentrations in women
WO2003018026A1 (en) Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2011064769A1 (en) Methods and pharmaceutical compositions for the treatment of hot flashes
AU2002313709A1 (en) As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
AU2002313708A1 (en) As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
CN1997357A (zh) 透皮或透粘膜应用活性剂的用途和制剂

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050720

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061221